Table 1.
S1 Studies in Advanced Gastric Cancer
| Abstract/author | Study agents | Patient number | Study Design | RR | PFS | OS |
| A4534/ Jeung et al. |
S1, Docetaxel, Cisplatin | 80 | Randomized phase II Docetaxel + S1 or Docetaxel + cisplatin | 44% 24% |
198 days 143 days (p = 0.03) |
NR |
| A4533/ Jin et al. |
S1 Cisplatin 5-FU |
230 | Randomized phase III S1 vs. S1 + cisplatin vs. 5-FU + cisplatin | 25% 38% 19% (p = 0.021) |
267 days 433 days 309 days (p = 0.008) |
NR |
| A4537/ Sato et al. |
S1 Docetaxel Cisplatin |
31 | Phase II study | 87% | 7.7 months | 19 months |
RR: Response rate; PFS: Progression-free survival; OS: Overall survival; NR: Not reported.